Taking Wackiness to new heights
Just when you think you have seen or heard it all something completely wacky comes out of nowhere that stuns you. This happened to me over the weekend when I heard perhaps the wackiest rumor ever and that’s saying something given, I’ve been doing this almost 30 years. It seems that troops at Abbott Diabetes Care believe the division is about to be sold. That Robert Ford Abbott CEO would...
The Arms Race Continues
It wasn’t that long ago that the USA and USSR engaged in a race to build the largest nuclear arms arsenal. Back in the day many of us became familiar with the term mutually assured destruction. Thankfully those days have passed and have now moved into our wacky world only it’s not the USA vs USSR but Novo Nordisk vs Lilly. Just this morning Novo made the following announcement- “Novo Nordisk...
The Vanity Factor
There’s a reason a historical perspective combined with “real” facts leads to common sense conclusions. Unlike what we are seeing as analysts who lack historical perspective and don’t bother to learn the facts spout their uninformed mostly useless opinions. Only problem is investors who rely on these analysts to provide informed analysis act on them. This is exactly what happened Tuesday when diabetes technology stocks git hammered. All of a sudden...
Let’s get VERY real.
Before we get into the Insulet earnings analysis it’s critical to get VERY real about how drugs like Ozempic and Mounjaro are impacting the overall diabetes market. As everyone should know by now, I am a huge fan of these drugs and the many follow-on offerings in development. As I noted in my post yesterday there are good reasons why shares of Lilly and Novo Nordisk are hitting new highs....
Rational Exuberance
Way back in the 1990’s during the dot com buddle then Federal Reserve Board chairman, Alan Greenspan uttered the now famous phrase “Irrational Exuberance” which many took as an indication that the stock market was overvalued. Today Lilly shares are soaring as sales of Mounjaro are skyrocketing taking Lilly shares along for a ride. Shares of their archrival Novo Nordisk are also soaring as the results of the SELECT trial...
Roller Coaster
One of my favorite Luke Bryan songs is Roller Coaster which when you think about it could be the theme song for Tandem. Here is a short history of Tandem as a publicly traded company. November 14, 2013, goes public closing at $192.60. September 28, 2016, the day Medtronic receives FDA approval for the 670G at the time the first hybrid closed loop insulin delivery system Tandem closes at $79.70. November 3, 2017,...
Taking a “pause”
When you’ve covered this wacky world as long as I have few things surprise you anymore. But once every now and then something new and/or different comes along that makes you sit up and take notice. This happened yesterday while reading the transcript from the Tandem earnings call – more on the results coming – the Tandem communications team has come up with a new term for patients who are...